1 Start 2 Complete InstructionsPlease complete the Module 3: Type 2 Diabetes Follow-up Survey and tell us what you learned from this module. Your response is important, and will be used to demonstrate the value of this educational program and to guide development of future CME activities. Thank you for your participation. Please provide your email so we can contact you with promotional information including drawings and prizes for completing this survey. This is optional. According to the criteria from the American Diabetes Association, which of the following HbA1c values are within the prediabetes range? * 5.8 - 6.2% 5.8- 6.4 % 5.7 - 6.5 % 5.6 - 6.3% 5.7 - 6.4% According to the American Diabetes Association guidelines, what should be the HbA1c goal in most healthy older adults? * <6.5% <6.5 - 7.0 % <7.0 - 7.5 % <8% Avoid reliance on HbA1c, instead focus on avoiding hypoglycemia and symptomatic hyperglycemia A patient with a history of type 2 diabetes on metformin monotherapy presents to you for follow-up. He is following appropriate lifestyle measures and is open to starting a second medication for his type 2 diabetes. To make the next step in deciding whether another medication should be started, you first should review: * The patient’s last A1c results Whether the patient has a history of cardiovascular disease, CKD, or heart failure The patient’s insurance The patient’s fasting fingerstick glucose values in his logbook For a T2DM patient who presents with heart failure, CKD, and with a GI disorder, which of the following therapies would be most appropriate? * GLP-1 RA with proven CV benefit SGLT2 inhibitor with proven CV benefit Either a GLP-1 RA or SGLT2 inhibitor with proven CV benefit A 65 y/o woman was admitted for acute myocardial infarction. Her ejection fraction is normal. She has known type 2 diabetes receiving metformin. Her renal function is normal and her HbA1c is 10.5%. For her diabetes, what is the best option? * An SGLT2 inhibitor Pioglitazone Basal insulin A GLP1 receptor agonist A combination GLP1 receptor agonist and basal insulin As time in range increases, risk of cardiovascular disease in T2DM patients ________. * Increases Decreases Stays the same Unsure How many patient encounters have you had in the last 90 days? * <200 200 400 600 800 1000 1200 >1200 As a result of this educational activity, did you make any changes to your clinical practice? * Yes No What specific changes did you make to your practice as a result of information received in this activity? (Select all that apply) * Consider the presence of (or risk factors for) HF, ASCVD, and CKD, when individualizing therapy in patients with type 2 diabetes Recommend CGM when appropriate to further inform treatment decisions and individualize antiglycemic therapy in patients with type 2 diabetes Consider insulin pumps or automated insulin delivery systems when appropriate for managing T2DM patients on insulin therapy Assess patients with diabetes for other comorbidities Screen at-risk patients for prediabetes or diabetes Refer patients with diabetes accordingly for further assessment of micro-and-macrovascular complications What additional improvements have you made in your clinical practice after participating in this activity? * What barriers are currently preventing you from making these changes? (select all that apply) * Formulary restrictions Insurance/financial issues Time constraints Lack of interprofessional team support System constraints Treatment related adverse events Patient adherence/compliance None Were the changes that you made in clinical practice beneficial to patient care?* * Yes No Has this course improved the comprehensive treatment of your patients with cardiometabolic disease or cardiometabolic risk? * Yes No Please explain your above answer. * Leave this field blank
